This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Is Sarepta Therapeutics (SRPT) Up 6.4% Since Last Earnings Report?
by Zacks Equity Research
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pfizer Discontinues Studies on DMD Candidate Domagrozumab
by Zacks Equity Research
Pfizer (PFE) terminates two clinical studies evaluating pipeline candidate, domagrozumab, in patients with duchenne muscular dystrophy.
Sarepta (SRPT) Q2 Loss Narrows, Exondys 51 Drives Sales
by Zacks Equity Research
Sarepta's (SRPT) loss per share is narrower than the Zacks Consensus Estimate while sales also beat the same. Exondys 51 continues its strong performance.
Implied Volatility Surging for Sarepta Therapeutics (SRPT) Stock Options
by Zacks Equity Research
Investors in Sarepta Therapeutics (SRPT) need to pay close attention to the stock based on moves in the options market lately.
Sarepta Therapeutics (SRPT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 8.51% and 3.66%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Jazz Pharma (JAZZ) Q2 Earnings Coming Up: What's in Store?
by Zacks Equity Research
Jazz's (JAZZ) Xyrem will likely continue to do well in the second quarter. Supply constraints will continue to hurt sales of Erwinaze.
Is a Beat in Store for BioDelivery (BDSI) in Q2 Earnings?
by Zacks Equity Research
Investor focus will be on the performance of BioDelivery Sciences' (BDSI) two marketed drugs, Belbuca (chronic pain) and Bunavail (opioid-dependence).
Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FNY
Sarepta's DMD Portfolio Solid, Sole Drug Dependence Concerns
by Zacks Equity Research
Sarepta Therapeutics' (SRPT) DMD drug sales are rising and pipeline candidates are progressing well. However, dependence on a single product for near-term growth is a concern.
DMD Research Veers Toward Gene Therapy: 3 Stocks in Focus
by Indrajit Bandyopadhyay
Investor focus is on the DMD segment this week with Sarepta presenting encouraging gene therapy study data and the FDA lifting its clinical hold on Solid Biosciences' gene therapy study.
Sarepta Pharma Pushes Two Biotech ETFs to New Highs
by Sweta Killa
The encouraging early trial results for a gene therapy for Duchenne muscular dystrophy pushed Sarepta Therapeutics and few biotech ETFs to new highs.
Company News For Jun 20, 2018
by Zacks Equity Research
Companies in the news are: T,FMI,COTV,SRPT
Biotech Stock Roundup: SRPT & SLDB Soar on Positive Data, ANIK & ZIOP Crash
by Zacks Equity Research
The biotech sector showed volatility with a few companies gaining on positive data readouts while a few plunging on dismal results.
Sarepta's Stock Soars on Encouraging Gene Therapy Results
by Zacks Equity Research
Sarepta (SRPT) shares skyrocket on better-than-expected results from an early-stage study, evaluating its gene therapy as a treatment for DMD patients.
Solid (SLDB) Surges as FDA Lifts Clinical Hold on DMD Drug
by Zacks Equity Research
Solid Biosciences' (SLDB) shares gained significantly after the FDA lifted the clinical hold on its phase I/II trial for its lead candidate, SGT-001 for DMD.
Options Traders Expect Huge Moves in Sarepta (SRPT) Stock
by Zacks Equity Research
Sarepta (SRPT) needs investors to pay close attention to the stock based on moves in the options market lately.
Sarepta Inks Manufacturing Deal for Gene Therapy Program
by Zacks Equity Research
Sarepta (SRPT) strikes manufacturing partnership with Brammer Bio to support its gene therapy development.
Here's Why Sarepta is Up More Than 60% So Far This Year
by Zacks Equity Research
Sarepta's (SRPT) key product, Exondys 51, continue to perform well and lead pipeline candidate, golodirsen, progresses well in 2018.
Sarepta (SRPT) Q1 Loss Narrows, Exondys 51 Sales Impress
by Zacks Equity Research
Sarepta (SRPT) reports narrower-than-expected loss for the first quarter of 2018. However, sales miss estimates.
Pfizer Starts Phase Ib for Duchenne Muscular Dystrophy Drug
by Zacks Equity Research
Pfizer (PFE) commences dosing in a phase Ib study, evaluating its gene therapy candidate, PF-06939926, for treating five to 12-yearold boys with duchenne muscular dystrophy.
Why Is Sarepta Therapeutics (SRPT) Up 19.3% Since Its Last Earnings Report?
by Zacks Equity Research
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Solid Biosciences (SLDB) Hit by Clinical Hold on Lead Drug
by Zacks Equity Research
Shares of Solid Biosciences (SLDB) were hit after the FDA put a clinical hold on a phase III study of lead DMD candidate, SGT-001.
Sarepta to Seek Rapid Approval for Second DMD Drug, Stock Up
by Zacks Equity Research
Sarepta (SRPT) will file a rolling NDA for its second DMD drug, golodirsen. The submission is expected to be completed in late 2018.
Zacks Investment Ideas feature highlights: Sarepta Therapeutics, bluebird bio, Editas Medicine, Align Technology and Intellia Therapeutics
by Zacks Equity Research
Zacks Investment Ideas feature highlights: Sarepta Therapeutics, bluebird bio, Editas Medicine, Align Technology and Intellia Therapeutics
Why Sarepta (SRPT) Jumped and We Sold
by Kevin Cook
Gains have rewarded the patient, but the long-term is balanced with obstacles still ahead in the FDA gauntlet